Characterization of the breast cancer associated ATM 7271T>G (V2424G) mutation by gene expression profiling

Genes Chromosomes and Cancer

Volumn 45, Issue 12, 2006, Pages 1169-1181

  Waddell, Nic ^a   Jonnalagadda, Jyoti ^a   Marsh, Anna ^a   Grist, Scott ^b   Jenkins, Mark ^c   Hobson, Karen ^a   Taylor, Malcolm ^d   Lindeman, Geoff J ^e,f   Tavtigian, Sean V ^g   Suthers, Graeme ^h   Goldgar, David ⁱ   Oefner, Peter J ^j   Taylor, Darrin ^k   Grimmond, Sean ^k   Khanna, Kum Kum ^a   Chenevix Trench, Georgia ^a,l  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

^g INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^h UNIVERSITY OF ADELAIDE   (Australia)

ⁱ UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF REGENSBURG   (Germany)

^k UNIVERSITY OF QUEENSLAND   (Australia)

^l ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN;

ARTICLE; ATAXIA TELANGIECTASIA; AUSTRALIA; AUTOSOMAL RECESSIVE DISORDER; BREAST CANCER; CANCER RISK; CHROMOSOME ABERRATION; CONTROLLED STUDY; DNA MICROARRAY; FAMILIAL CANCER; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; IONIZING RADIATION; LYMPHOBLASTOID CELL; MAJOR CLINICAL STUDY; MISSENSE MUTATION; PENETRANCE; PHYLOGENY; PRIORITY JOURNAL; RADIATION EXPOSURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; UNITED KINGDOM;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CONSERVED SEQUENCE; DNA-BINDING PROTEINS; EXONS; FAMILY; GENE EXPRESSION PROFILING; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PENETRANCE; PHYLOGENY; PROTEIN-SERINE-THREONINE KINASES; SEQUENCE ALIGNMENT; TUMOR SUPPRESSOR PROTEINS;

ATAXIA TELANGIECTASIA;

EID: 33751114970     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20381     Document Type: Article

References (48)

1. Antoniou A, Pharoah P, Narod S, Risch H, Eyfjord J, Hopper J, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF. 2003. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 72:1117-1130.
2. Athma P, Rappaport R, Swift M. 1996. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cyrogenet 92:330-134.
3. Bar J, Cohen-Noyman E, Geiger B, Oren M. 2004. Attenuation of the p53 response to DNA damage by high cell density. Oncogene 23:2128-2137.
4. Barlund M, Monni O, Weaver JD, Kauraniemi P, Sauter G, Heiskanen M, Kallioniemi OP, Kallioniemi A. 2002. Cloning of BCAS3 (17q23) and BCAS4 (20q13) genes that undergo amplification, overexpression, and fusion in breast cancer. Genes Chromosomes Cancer 35:311-317.
5. Bebb D, Yu Z, Chen J, Telatar M, Gelmon K, Phillips N, Gatti R, Glickman B. 1999. Absence of mutations in the ATM gene in forty-seven cases of sporadic breast cancer. Br J Cancer 80:1979-1981.
6. Bernstein JE, Bernstein L, Thompson WD, Lynch CF, Malone KE, Teitelbaum SL, Olsen JH, Anton-Culver H, Boice JD, Rosenstein BS, Børresen-Dale A-L, Gatti RA, Concannon P, WECARE Study Collaborative Group, Haile RW. 2003. ATM variants 7271T>G and IVS10-6T>G among women with unilateral and bilateral breast cancer. Br J Cancer 89:1513-1516.
7. Bernstein JL, Teraoka S, Southey MC, Jenkins MA, Andrulis IL, Knight JA, John EM, Lapinski R, Wolitzer AL, Whittemore AS, West D, Seminara D, Olson ER, Spurdle AB, Chenevix-Trench G, Giles GG, Hopper JL, Concannon P. 2006. Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the breast cancer family registry. Hum Mutat, in press.
8. Challen G, Martinez G, Davis M, Taylor D, Crowe M, Teasdale R, Grimmond S, Little M. 2004. Identifying the molecular phenotype of renal progenitor cells. J Am Soc Nephrol 15:2344-2357.
9. Chen J, Birkholtz GG, Lindblom P, Rubio C, Lindblom A. 1998. The role of ataxia-telangiectasia heterozygotes in familial breast cancer. Cancer Res 58:1376-1379.
10. Chen P, Gatei M, O'Connell M, Khanna K, Bugg S, Hogg A, Scott S, Hobson K, Lavin M. 1999. Chk1 complements the G2/M checkpoint defect and radiosensitivity of ataxia-telangiectasia cells. Oncogene 18:249-
11. Trench G, Spurdle A, Gatei M, Kelly H, Marsh A, Chen X, Donn K, Cummings M, Nyholt D, Jenkins M, Scott C, Pupo GM, Dörk T, Bendix R, Kirk J, Tucker K, McCredie MRE, Hopper JL, Sambrook J, Mann GJ, Khanna KK. 2002a. Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst 94:205-215.
12. Chenevix-Trench G, Spurdle A, Gatei M, Kelly H, Marsh A, Chen X, Donn K, Cummings M, Nyholt D, Jenkins M, Scott C, Pupo GM, Dork T, Bendix R, Kirk J, Tucker K, McCredie MRE, Hopper JL, Sambrook J, Mann GJ, Khanna KK. 2002b. Dominant negative ATM mutations in breast cancer families: Erratum. J Natl Cancer Inst 94:952.
13. Di Fiore B, Ciciarello M, Mangiacasale R, Palena A, Tassin A-M, Cundari E, Lavia P. 2003. Mammalian RanBP1 regulates centrosome cohesion during mitosis. J Cell Sci 116:3399-3411.
14. Fernet M, Moullan N, Lauge A, Stoppa-Lyonnet D, Hall J. 2004. Cellular responses to ionising radiation of AT heterozygotes: Differences between missense and truncating mutation carriers. Br J Cancer 90:866-873.
15. FitzGerald M, Bean J, Hegde S, Unsal H, MacDonald D, Harkin D, Finkelstein D, Isselbacher K, Haber D. 1997. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet 15:307-310.
16. Gatei M, Shkedy D, Khanna K, Uziel T, Shiloh Y, Pandita T, Lavin M, Rotman G. 2001. Ataxia-telangiectasia: Chronic activation of damage-responsive functions is reduced by a-lipoic acid. Oncogene 20:289-294.
17. Gatti R, Tward A, Concannon P. 1999. Cancer risk in ATM Heterozygotes: A model of phenotypic and mechanistic differences between missense and truncating mutations. Mol Genet Metab 68:419-423.
18. Geoffroy-Perez B, Janin N, Ossian K, Lauge A, Croquette M, Griscelli C, Debre M, Bressac-de-Paillerets B, Aurias A, Stoppa-Lyonnet D, Andrieu N. 2003. Cancer risk in heterozygotes for ataxia-telangiectasia. Int J Caneer 93:288-293.
19. Gutierrez-Enriquez S, Fernet M, Dork T, Bremer M, Lauge A, Stoppa-Lyonnet D, Moullan N, Angele S, Hall J. 2004. Functional consequences of ATM sequence variants for chromosomal radiosensitivity. Genes Chromosomes Cancer 40:109-119.
20. Hosack D, Dennis G, Jr., Sherman B, Lane H, Lempicki R. 2003. Identifying biological themes within lists of genes with EASE. Genome Biol 4:R70.
21. Inskip H, Kinlen L, Taylor A, Woods C, Arlett C. 1999. Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia. Br J Cancer 79:1304-1307.
22. Janin N, Andrieu N, Ossian K, Laugé A, Croquette M-F, Griscelli C, Debré M, Bressac-de-Paillerets B, Aurias A, StoppaLyonnet D. 1999. Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: Haplotype study in French AT families. Br J Caneer 80:1042-1045.
23. Khanna K, Jackson S. 2001. DNA double-strand breaks: Signaling, repair and the cancer connection. Nat Genet 27:247-254.
24. Khanna K, Keating K, Kozlov S, Scott S, Gatei M, Hobson K, Taya Y, Gabrielli B, Chan D, Lees-Miller S, Lavin MF. 1998. ATM associates with and phospharylates p53: Mapping the region of interaction. Nat Genet 20:398-400.
25. Lange K, Weeks D. Boehnke M. 1988. Programs for pedigree analysis: MENDEL, FISHER, and dGENE. Genet Epidemiol 5:471, 472.
26. Mann G, Thorne H, Balleine R, Butow P, Clarke C, Edkins E, Evans G, Fereday S, Haan E, Gattas M, Giles GG, Goldblatt J, Hopper JL, Kirk J, Leary JA, Lindeman G, Niedermayr E, Phillips K-A, Picken S, Pupo GM, Saunders C, Scott CL, Spurdle AB, Suthers G, Tucker K, Chenevix-Trench G, Kathleen Cuningham Consortium for Research in Familial Breast Cancer. 2006. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res 8:R12.
27. Mathe E, Olivier M, Kato S, Ishioka C, Hainaut P, Tavtigian S. 2006. Computational approaches for predicting the biological effect of p53 missense mutations: A comparison of 3 sequence analysis based methods. Nucleic Acids Res 5:1317-1325.
28. Ng P, Henikoff S. 2003. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 31:3812-3814.
29. Olsen J, Hahnemann J, Børresen-Dale A-L, Børndum-Nielsen K, Hammarström L, Kleinerman R, Kääriäinen H, Lönnqvist T, Sankila R, Seersholm N, Tretli S, Yuen J, Boice JD, Tucker M. 2001. Cancer in patients with ataxia-telangiectasia and in their relatives in the Nordic countries. J Natl Cancer Inst 93:121-127.
30. Olsen J, Hahnemann J, Børrescn-Dale A-L, Tretli S, Kleinerman R, Sankila R, Hammarström L, Robsahm T, Kääriäinen H, Bregard A, Børndum-Nielsen K, Yuen J, Tucker M. 2005. Breast and other cancers in 1445 blood relatives of 75 Nordic patients with ataxia telangiectasia. Br J Cancer 93:260-265.
31. Poirot O, Suhre K, Abergel C, O'Toole E, Notredame C. 2004. 3DCoffee@igs: A web server for combining sequences and structures into a multiple sequence alignment. Nucleic Acids Res 32: w37-w40.
32. Saal LH, Troein C, Vallon-Christersson J, Gruvberger S, Borg A, Peterson C. 2002. BioArray Software Environment (BASE): A platform for comprehensive management and analysis of microarray data. Genome Biol 3:SOFTWARE0003.
33. Shayeghi M, Seal S, Regan J, Collins N, Barfoot R, Rahman N, Ashton A, Moohan M, Wooster K, Owen R, Bliss JM, Stratton MR, Yarnold J. 1998. Heterozygosity for mutations in the ataxia telangiectasia gene is not a major cause of radiotherapy complications in breast cancer patients. Br J Cancer 78:922-927.
34. Smyth GK. 2004. Linear models and empirical haves methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
35. Sommer S, Jiang Z, Feng J, Buzin C, Zheng J, Longmate J, Jung M, Moulds J, Dritschilo A. 2003. ATM missense mutations are frequent in patients with breast cancer. Cancer Genet Cytogenet 145:115-120.
36. Stankovic T, Hubank M, Cronin D, Stewart G, Fletcher D, Bignell C, Alvi A, Austen B, Weston V, Fegan C, Byrd PJ, Moss PAH, Taylor AMR. 2004. Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNAdamage but are distinguished by major differences in activating prosurvival responses. Blood 103:291-300.
37. Stankovic T, Kidd A, Sutcliffe A, McGuire G, Robinson P, Weber P, Bedenham T, Bradwell A, Easton D, Lennox G, Haites N, Byrd PJ, Taylor AMR. 1998. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: Expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet 62:334-345.
38. Stewart G, Last J, Stankovic T, Haites N, Kidd A, Byrd P, Taylor A. 2001. Residual ataxia telangiectasia mutated protein function in cells from ataxia telangiectasia patients, with 5762ins137 and 7271T3G mutations, showing a less severe phenotype. J Biol Chem 276:30133-30141.
39. Su Y, Swift M. 2000. Mortality rates among carriers of ataxia telangiectasia mutant allcles. Ann Int Med 133:770-778.
40. Swift M, Sholman L, Perry M, Chase C. 1976. Malignant neoplasms in the families of patients with ataxia-telangiectasia. Cancer Res 36:209-215.
41. Szabo C, Schutte M, Broeks A, Houwing-Duistermaat J, Thorstenson Y, Durocher F, Oldenburg R, Wasielewski M, Odefrey F, Thompson D, Floore AN, Kraan J, Klijn JGM, van den Ouweland AMW, the BRCA-X Consortium, Cooperative Family Registry Breast Cancer Study, Interdisciplinary Health Research International Team on Breast Cancer Susceptibility. Wagner TMU, Devilee P, Simard J, van't Veer LJ, Goldgar DE, Meijers-Heijboer H. 2004. Are ATM mutations 7271T3G and IVS10-6T3G really high-risk breast cancer-susceptibility alleles? Cancer Res 64:840-843.
42. Tavtigian SV, Deffenbangh AM, Yin L, Judkins T, Scholl T, Samollow PB, de Silva D, Zharkikh A, Thomas A. 2006. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 43:295-305.
43. Thompson IJ, Antonion AC, Jenkins M, Marsh A, Chen X, Wayne T, Tesoriero A, Milne R, Spurdle A, Thorstenson V, Southey M, Giles GG, kConFab Investigators, Khanna KK, Sambrook J, Oefner P, Goldgar D, Hopper JL, Easton DF, Chenevix-Trench G. 2005a. Two ATM variants and breast cancer risk. Hum Mutat 25:594, 595.
44. Thompson D, Duedal S, Kirner J, McGuffog L, Last J, Reiman A, Byrd P, Taylor M, Easton D. 2005b. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 97:813-822.
45. Thompson D, Easton D, Goldgar D. 2003. A full-likelihood method for the evaluation of causality of sequence variants from family data. Am J Hum Genet 73:652-6555.
46. Vorechovsky I, Rasio D, Luo L, Monaco C, Hammarstrom L, Webster AD, Zaloudik J, Barhanti-Brodani G, James M, Russo G. 1996. The ATM gene and susceptibility to breast cancer: Analysis of 38 breast tumors reveals no evidence for mutation. Cancer Res 56:2726-2732.
47. Watts J, Morley M, Burdick J, Fiori J, Ewens W, Spielman R, Cheung V. 2002. Gene expression phenotype in heterozygous carriers of ataxia telangieetasia. Am J Hum Genet 71:791-800.
48. Wiencke J, Wara D, Little J, Kelsey K. 1992. Heterogeneity in the elastogenic response to X-rays in lymphocytes from ataxia-telangiectasia heterozygotes and controls. Cancer Causes Control 3:237-245.